Ganaxolone: First FDA-approved Medicine for the Treatment of Seizures Associated with Cyclin-dependent Kinase-like 5 Deficiency Disorder
Author:
- 1 February 2024
- journal article
- research article
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 31 (4) , 388-392
Abstract
The neurosteroids progesterone and allopregnanolone control numerous neuroprotective functions in neural tissues, including inhibition of epileptic seizures and cell death. Ganaxolone (3α-hydroxy-3β-methyl-5α-pregnan-20-one) (GNX) is the 3β- methylated synthetic analog of allopregnanolone and an allosteric GABAA positive modulator. Ganaxolone reduces the frequency of CDD-associated seizures.Keywords
This publication has 23 references indexed in Scilit:
- Cyclin-Dependent Kinase-Like 5 Deficiency Disorder: Clinical ReviewPediatric Neurology, 2019
- Histone deacetylases mediate GABAA receptor expression, physiology, and behavioral maladaptations in rat models of alcohol dependenceNeuropsychopharmacology, 2018
- Ganaxolone suppression of behavioral and electrographic seizures in the mouse amygdala kindling modelEpilepsy Research, 2010
- Development of new antiepileptic drugs: challenges, incentives, and recent advancesThe Lancet Neurology, 2007
- Clinical Evaluation of Ganaxolone in Pediatric and Adolescent Patients with Refractory EpilepsyEpilepsia, 2007
- GanaxoloneNeurotherapeutics, 2007
- Neurosteroids: endogenous regulators of the GABAA receptorNature Reviews Neuroscience, 2005
- Allopregnanolone Analogs That Positively Modulate GABAA Receptors Protect against Partial Seizures Induced by 6‐Hz Electrical Stimulation in MiceEpilepsia, 2004
- Acute and chronic effects of the synthetic neuroactive steroid, ganaxolone, against the convulsive and lethal effects of pentylenetetrazol in seizure-kindled mice: comparison with diazepam and valproateNeuropharmacology, 2000
- Initial Human Experience with Ganaxolone, a Neuroactive Steroid with Antiepileptic ActivityEpilepsia, 1997